Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPhASIS trial of vidofludimus calcium (IMU-838) in relapsing-remitting multiple sclerosis
2024-516739-29-00Phase 2Authorised
- Sponsor
- Immunic Therapeutics
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS) (5 cohorts), sponsored by Immunic Therapeutics. Planned start Jan 2019; status: authorised.
02
Drugs
vidofludimus calcium
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2024-516739-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516739-29-00.